Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 261 entries
Sorted by: Best Match Show Resources per page
International Symposium on Progesterone and Progestins : Paris, May 7-9, 1981.

Journal of endocrinological investigation

[No authors listed]
PMID: 27518256
J Endocrinol Invest. 1980 Jul;3(3):337. doi: 10.1007/BF03348290.

No abstract available.

Cite
International Symposium on Progesterone and Progestins : Paris, May 7-9, 1981. J Endocrinol Invest. 1980;3(3):337doi: 10.1007/BF03348290.
(1980). International Symposium on Progesterone and Progestins : Paris, May 7-9, 1981. Journal of endocrinological investigation, 3(3), 337. https://doi.org/10.1007/BF03348290
"International Symposium on Progesterone and Progestins : Paris, May 7-9, 1981." Journal of endocrinological investigation vol. 3,3 (1980): 337. doi: https://doi.org/10.1007/BF03348290
International Symposium on Progesterone and Progestins : Paris, May 7-9, 1981. J Endocrinol Invest. 1980 Jul;3(3):337. doi: 10.1007/BF03348290. PMID: 27518256.
Copy Download .nbib Format: NLM
Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial.

Electronic physician

Bafghi AS, Bahrami E, Sekhavat L.
PMID: 26516434
Electron Physician. 2015 Oct 19;7(6):1301-9. doi: 10.14661/1301. eCollection 2015 Oct.

BACKGROUND: Preterm birth is a worldwide health concern due to its various negative consequences. Therefore, the prevention of preterm birth is a top priority for healthcare systems in all countries.OBJECTIVE: To compare the effectiveness of vaginal versus intramuscular progesterone...

Cite
Bafghi AS, Bahrami E, Sekhavat L. Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial. Electron Physician. 2015;7(6):1301-9doi: 10.14661/1301.
Bafghi, A. S., Bahrami, E., & Sekhavat, L. (2015). Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial. Electronic physician, 7(6), 1301-9. https://doi.org/10.14661/1301
Bafghi, Afsar Sadat Tabatabaei, et al. "Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial." Electronic physician vol. 7,6 (2015): 1301-9. doi: https://doi.org/10.14661/1301
Bafghi AS, Bahrami E, Sekhavat L. Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial. Electron Physician. 2015 Oct 19;7(6):1301-9. doi: 10.14661/1301. eCollection 2015 Oct. PMID: 26516434; PMCID: PMC4623787.
Copy Download .nbib Format: NLM
Evaluation of the treatment patterns and economic burden of dysmenorrhea in Japanese women, using a claims database.

ClinicoEconomics and outcomes research : CEOR

Akiyama S, Tanaka E, Cristeau O, Onishi Y, Osuga Y.
PMID: 28579813
Clinicoecon Outcomes Res. 2017 May 22;9:295-306. doi: 10.2147/CEOR.S127760. eCollection 2017.

PURPOSE: This study aimed to describe treatment patterns and estimate health care resource utilization and associated costs among Japanese women with dysmenorrhea, using a claims database.METHODS: This was a retrospective analysis using health insurance data from the Japan Medical...

Cite
Akiyama S, Tanaka E, Cristeau O, et al. Evaluation of the treatment patterns and economic burden of dysmenorrhea in Japanese women, using a claims database. Clinicoecon Outcomes Res. 2017;9:295-306doi: 10.2147/CEOR.S127760.
Akiyama, S., Tanaka, E., Cristeau, O., Onishi, Y., & Osuga, Y. (2017). Evaluation of the treatment patterns and economic burden of dysmenorrhea in Japanese women, using a claims database. ClinicoEconomics and outcomes research : CEOR, 9295-306. https://doi.org/10.2147/CEOR.S127760
Akiyama, Sayako, et al. "Evaluation of the treatment patterns and economic burden of dysmenorrhea in Japanese women, using a claims database." ClinicoEconomics and outcomes research : CEOR vol. 9 (2017): 295-306. doi: https://doi.org/10.2147/CEOR.S127760
Akiyama S, Tanaka E, Cristeau O, Onishi Y, Osuga Y. Evaluation of the treatment patterns and economic burden of dysmenorrhea in Japanese women, using a claims database. Clinicoecon Outcomes Res. 2017 May 22;9:295-306. doi: 10.2147/CEOR.S127760. eCollection 2017. PMID: 28579813; PMCID: PMC5446961.
Copy Download .nbib Format: NLM
Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells.

Oncotarget

Willibald M, Bayer G, Stahlhut V, Poschmann G, Stühler K, Gierke B, Pawlak M, Seeger H, Mueck AO, Niederacher D, Fehm T, Neubauer H.
PMID: 29069804
Oncotarget. 2017 Aug 02;8(42):72480-72493. doi: 10.18632/oncotarget.19819. eCollection 2017 Sep 22.

Menopausal hormone therapy, using estrogen and synthetic progestins, is associated with an increased risk of developing breast cancer. The effect of progestins on breast cells is complex and not yet fully understood. In previous

Cite
Willibald M, Bayer G, Stahlhut V, et al. Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget. 2017;8(42):72480-72493doi: 10.18632/oncotarget.19819.
Willibald, M., Bayer, G., Stahlhut, V., Poschmann, G., Stühler, K., Gierke, B., Pawlak, M., Seeger, H., Mueck, A. O., Niederacher, D., Fehm, T., & Neubauer, H. (2017). Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget, 8(42), 72480-72493. https://doi.org/10.18632/oncotarget.19819
Willibald, Marina, et al. "Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells." Oncotarget vol. 8,42 (2017): 72480-72493. doi: https://doi.org/10.18632/oncotarget.19819
Willibald M, Bayer G, Stahlhut V, Poschmann G, Stühler K, Gierke B, Pawlak M, Seeger H, Mueck AO, Niederacher D, Fehm T, Neubauer H. Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget. 2017 Aug 02;8(42):72480-72493. doi: 10.18632/oncotarget.19819. eCollection 2017 Sep 22. PMID: 29069804; PMCID: PMC5641147.
Copy Download .nbib Format: NLM
Oncofertility in Canada: gonadal protection and fertility-sparing strategies.

Current oncology (Toronto, Ont.)

Ronn R, Holzer HE.
PMID: 24311962
Curr Oncol. 2013 Dec;20(6):e602-7. doi: 10.3747/co.20.1359.

BACKGROUND: Cancer can be a devastating diagnosis. In particular, malignancy and its indicated treatments have profoundly negative effects on the fertility of young cancer patients. Oncofertility has emerged as a new interdisciplinary field to address the issue of gonadotoxicity...

Cite
Ronn R, Holzer HE. Oncofertility in Canada: gonadal protection and fertility-sparing strategies. Curr Oncol. 2013;20(6):e602-7doi: 10.3747/co.20.1359.
Ronn, R., & Holzer, H. E. (2013). Oncofertility in Canada: gonadal protection and fertility-sparing strategies. Current oncology (Toronto, Ont.), 20(6), e602-7. https://doi.org/10.3747/co.20.1359
Ronn, R, and Holzer, H E G. "Oncofertility in Canada: gonadal protection and fertility-sparing strategies." Current oncology (Toronto, Ont.) vol. 20,6 (2013): e602-7. doi: https://doi.org/10.3747/co.20.1359
Ronn R, Holzer HE. Oncofertility in Canada: gonadal protection and fertility-sparing strategies. Curr Oncol. 2013 Dec;20(6):e602-7. doi: 10.3747/co.20.1359. PMID: 24311962; PMCID: PMC3851358.
Copy Download .nbib Format: NLM
Breast cancer in the setting of fertility-sparing treatment for endometrial cancer.

Gynecologic oncology reports

Moss HA, Frey MK, Blank SV.
PMID: 26075999
Gynecol Oncol Rep. 2014 Oct 27;10:30-1. doi: 10.1016/j.gore.2014.10.002. eCollection 2014 Dec.

•Progesterone therapy is a commonly used alternative to surgical management for women with endometrial cancer who desire fertility preservation.•Prior research suggests that progestins may contribute to breast tumorigenesis.•We report a patient diagnosed with progesterone receptor positive breast cancer during...

Cite
Moss HA, Frey MK, Blank SV. Breast cancer in the setting of fertility-sparing treatment for endometrial cancer. Gynecol Oncol Rep. 2014;10:30-1doi: 10.1016/j.gore.2014.10.002.
Moss, H. A., Frey, M. K., & Blank, S. V. (2014). Breast cancer in the setting of fertility-sparing treatment for endometrial cancer. Gynecologic oncology reports, 1030-1. https://doi.org/10.1016/j.gore.2014.10.002
Moss, Haley A, et al. "Breast cancer in the setting of fertility-sparing treatment for endometrial cancer." Gynecologic oncology reports vol. 10 (2014): 30-1. doi: https://doi.org/10.1016/j.gore.2014.10.002
Moss HA, Frey MK, Blank SV. Breast cancer in the setting of fertility-sparing treatment for endometrial cancer. Gynecol Oncol Rep. 2014 Oct 27;10:30-1. doi: 10.1016/j.gore.2014.10.002. eCollection 2014 Dec. PMID: 26075999; PMCID: PMC4434147.
Copy Download .nbib Format: NLM
Menstrual suppression: current perspectives.

International journal of women's health

Hillard PA.
PMID: 25018654
Int J Womens Health. 2014 Jun 23;6:631-7. doi: 10.2147/IJWH.S46680. eCollection 2014.

Menstrual suppression to provide relief of menstrual-related symptoms or to manage medical conditions associated with menstrual morbidity or menstrual exacerbation has been used clinically since the development of steroid hormonal therapies. Options range from the extended or continuous use...

Cite
Hillard PA. Menstrual suppression: current perspectives. Int J Womens Health. 2014;6:631-7doi: 10.2147/IJWH.S46680.
Hillard, P. A. (2014). Menstrual suppression: current perspectives. International journal of women's health, 6631-7. https://doi.org/10.2147/IJWH.S46680
Hillard, Paula Adams. "Menstrual suppression: current perspectives." International journal of women's health vol. 6 (2014): 631-7. doi: https://doi.org/10.2147/IJWH.S46680
Hillard PA. Menstrual suppression: current perspectives. Int J Womens Health. 2014 Jun 23;6:631-7. doi: 10.2147/IJWH.S46680. eCollection 2014. PMID: 25018654; PMCID: PMC4075955.
Copy Download .nbib Format: NLM
Adenomyosis: a systematic review of medical treatment.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S.
PMID: 27379972
Gynecol Endocrinol. 2016 Sep;32(9):696-700. doi: 10.1080/09513590.2016.1197200. Epub 2016 Jul 05.

Adenomyosis is a heterogeneous gynaecologic condition with a range of clinical presentations, the most common being heavy menstrual bleeding and dysmenorrhoea; however, patients can also be asymptomatic. Several studies support the theory that adenomyosis results from invasion of the...

Cite
Pontis A, D'Alterio MN, Pirarba S, et al. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016;32(9):696-700doi: 10.1080/09513590.2016.1197200.
Pontis, A., D'Alterio, M. N., Pirarba, S., de Angelis, C., Tinelli, R., & Angioni, S. (2016). Adenomyosis: a systematic review of medical treatment. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 32(9), 696-700. https://doi.org/10.1080/09513590.2016.1197200
Pontis, A, et al. "Adenomyosis: a systematic review of medical treatment." Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology vol. 32,9 (2016): 696-700. doi: https://doi.org/10.1080/09513590.2016.1197200
Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol Endocrinol. 2016 Sep;32(9):696-700. doi: 10.1080/09513590.2016.1197200. Epub 2016 Jul 05. PMID: 27379972.
Copy Download .nbib Format: NLM
Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis.

Biology of sex differences

Tack LJ, Craen M, Dhondt K, Vanden Bossche H, Laridaen J, Cools M.
PMID: 26885361
Biol Sex Differ. 2016 Feb 16;7:14. doi: 10.1186/s13293-016-0067-9. eCollection 2016.

BACKGROUND: Prior to the start of cross-sex hormone therapy (CSH), androgenic progestins are often used to induce amenorrhea in female to male (FtM) pubertal adolescents with gender dysphoria (GD). The aim of this single-center study is to report changes...

Cite
Tack LJ, Craen M, Dhondt K, et al. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. Biol Sex Differ. 2016;7:14doi: 10.1186/s13293-016-0067-9.
Tack, L. J., Craen, M., Dhondt, K., Vanden Bossche, H., Laridaen, J., & Cools, M. (2016). Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. Biology of sex differences, 714. https://doi.org/10.1186/s13293-016-0067-9
Tack, Lloyd J W, et al. "Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis." Biology of sex differences vol. 7 (2016): 14. doi: https://doi.org/10.1186/s13293-016-0067-9
Tack LJ, Craen M, Dhondt K, Vanden Bossche H, Laridaen J, Cools M. Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis. Biol Sex Differ. 2016 Feb 16;7:14. doi: 10.1186/s13293-016-0067-9. eCollection 2016. PMID: 26885361; PMCID: PMC4754845.
Copy Download .nbib Format: NLM
New insight on a possible mechanism of progestogens in terms of breast cancer risk.

Hormone molecular biology and clinical investigation

Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO.
PMID: 25961254
Horm Mol Biol Clin Investig. 2011 Apr 01;6(1):185-92. doi: 10.1515/HMBCI.2010.082.

OBJECTIVES: Progestogens influence mammary gland development and probably breast cancer tumorigenesis by regulating a broad spectrum of physiological processes. We investigated receptor membrane-initiated actions of progestogens in MCF-7 breast cancer cells overexpressing progesterone receptor membrane component 1 (PGRMC1).DESIGN: MCF-7...

Cite
Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig. 2011;6(1):185-92doi: 10.1515/HMBCI.2010.082.
Neubauer, H., Chen, R., Schneck, H., Knorrp, T., Templin, M. F., Fehm, T., Cahill, M. A., Seeger, H., Yu, Q., & Mueck, A. O. (2011). New insight on a possible mechanism of progestogens in terms of breast cancer risk. Hormone molecular biology and clinical investigation, 6(1), 185-92. https://doi.org/10.1515/HMBCI.2010.082
Neubauer, Hans, et al. "New insight on a possible mechanism of progestogens in terms of breast cancer risk." Hormone molecular biology and clinical investigation vol. 6,1 (2011): 185-92. doi: https://doi.org/10.1515/HMBCI.2010.082
Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig. 2011 Apr 01;6(1):185-92. doi: 10.1515/HMBCI.2010.082. PMID: 25961254.
Copy Download .nbib Format: NLM
Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells.

Hormone molecular biology and clinical investigation

Seeger H, Ruan X, Neubauer H, Mueck AO.
PMID: 25961257
Horm Mol Biol Clin Investig. 2011 May 01;6(2):211-4. doi: 10.1515/HMBCI.2011.008.

BACKGROUND: Proliferation of human breast epithelial cells is regulated by sex hormones. Epidemiological studies indicate that progestogen addition to estrogen therapy can increase breast cancer risk. However, it remains unclear if all progestogens react in a similar manner. Here,...

Cite
Seeger H, Ruan X, Neubauer H, et al. Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Horm Mol Biol Clin Investig. 2011;6(2):211-4doi: 10.1515/HMBCI.2011.008.
Seeger, H., Ruan, X., Neubauer, H., & Mueck, A. O. (2011). Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Hormone molecular biology and clinical investigation, 6(2), 211-4. https://doi.org/10.1515/HMBCI.2011.008
Seeger, Harald, et al. "Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells." Hormone molecular biology and clinical investigation vol. 6,2 (2011): 211-4. doi: https://doi.org/10.1515/HMBCI.2011.008
Seeger H, Ruan X, Neubauer H, Mueck AO. Effect of drospirenone on proliferation of human benign and cancerous epithelial breast cells. Horm Mol Biol Clin Investig. 2011 May 01;6(2):211-4. doi: 10.1515/HMBCI.2011.008. PMID: 25961257.
Copy Download .nbib Format: NLM
Neurosteroids in clinical practice: implications for women's health.

Hormone molecular biology and clinical investigation

Genazzani AR, Bucci F, Russo N, Daino D, Santoro AN, Pluchino N.
PMID: 25961341
Horm Mol Biol Clin Investig. 2011 Oct 01;7(3):413-23. doi: 10.1515/HMBCI.2011.120.

The steroidogenic endocrine glands and local synthesis both contribute to the pool of steroids present in the central nervous system (CNS) and peripheral nervous system (PNS). Although the synthesis of neurosteroids in the nervous system is now well established,...

Cite
Genazzani AR, Bucci F, Russo N, et al. Neurosteroids in clinical practice: implications for women's health. Horm Mol Biol Clin Investig. 2011;7(3):413-23doi: 10.1515/HMBCI.2011.120.
Genazzani, A. R., Bucci, F., Russo, N., Daino, D., Santoro, A. N., & Pluchino, N. (2011). Neurosteroids in clinical practice: implications for women's health. Hormone molecular biology and clinical investigation, 7(3), 413-23. https://doi.org/10.1515/HMBCI.2011.120
Genazzani, Andrea Riccardo, et al. "Neurosteroids in clinical practice: implications for women's health." Hormone molecular biology and clinical investigation vol. 7,3 (2011): 413-23. doi: https://doi.org/10.1515/HMBCI.2011.120
Genazzani AR, Bucci F, Russo N, Daino D, Santoro AN, Pluchino N. Neurosteroids in clinical practice: implications for women's health. Horm Mol Biol Clin Investig. 2011 Oct 01;7(3):413-23. doi: 10.1515/HMBCI.2011.120. PMID: 25961341.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 261 entries